NOS2 and stroke disorder: Microglia-specific deletion or pharmacological inhibition of HDAC3 reduces expression of TNF α, IL 1β, IL 6, and iNOS, represses NF-κB targets, shifts the microglial phenotype toward an anti-inflammatory state, and improves stroke outcomes [41].